The company conducts business under
Healthcare sector and is part of
Health Information Services industry.
The entity has a beta of 1.8533, which indicates a somewhat significant risk relative to the market. Let's try to break down what Tabula's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tabula Rasa will likely underperform. Even though it is essential to pay attention to
Tabula Rasa Healthcare current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Tabula Rasa Healthcare exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Tabula Rasa Healthcare has an expected return of -0.55%. Please be advised to validate Tabula Rasa
information ratio,
downside variance,
day median price, as well as the
relationship between the
treynor ratio and
kurtosis to decide if
Tabula Rasa Healthcare performance from the past will be repeated at some point in the near future.
How important is Tabula Rasa's Liquidity
Tabula Rasa
financial leverage refers to using borrowed capital as a funding source to finance Tabula Rasa HealthCare ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Tabula Rasa financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Tabula Rasa's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Tabula Rasa's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Tabula Rasa's total debt and its cash.
What is the case for Tabula Rasa Investors
Tabula Rasa Healthcare reported the previous year's revenue of 322.63
M. Net Loss for the year was (88.31
M) with profit before overhead, payroll, taxes, and interest of 92.41
M.
Will Tabula Rasa growth be rational after the rise?
Current value at risk indicator falls down to -8.95. Possible price jump? Tabula Rasa Healthcare is displaying above-average volatility over the selected time horizon. Investors should scrutinize Tabula Rasa Healthcare independently to ensure intended market timing strategies are aligned with expectations about Tabula Rasa volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tabula Rasa's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tabula Rasa's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Tabula Rasa Implied Volatility
Tabula Rasa's implied volatility exposes the market's sentiment of Tabula Rasa Healthcare stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Tabula Rasa's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Tabula Rasa stock will not fluctuate a lot when Tabula Rasa's options are near their expiration.
Our Final Take On Tabula Rasa
Whereas some companies within the health information services industry are still a little expensive, even after the recent corrections, Tabula Rasa may offer a potential longer-term growth to investors. To summarize, as of the 5th of March 2022, our concluding 90 days buy vs. sell advice on the company is
Strong Sell. However, we believe Tabula Rasa is
undervalued with
low chance of financial distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Tabula Rasa HealthCare. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]